Iorgulescu, J. B., Sun, C., Neff, C., Cioffi, G., Gutierrez, C., Kruchko, C., … Barnholtz-Sloan, J. S. (2023). Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol, 25(2), 424–429. https://doi.org/10.1093/neuonc/noac270

Iorgulescu, J Bryan, Chuxuan Sun, Corey Neff, Gino Cioffi, Catherine Gutierrez, Carol Kruchko, Jennifer Ruhl, et al. “Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.” Neuro Oncol 25, no. 2 (February 14, 2023): 424–29. https://doi.org/10.1093/neuonc/noac270.

Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, et al. Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol. 2023 Feb 14;25(2):424–9.

Iorgulescu, J. Bryan, et al. “Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.” Neuro Oncol, vol. 25, no. 2, Feb. 2023, pp. 424–29. Pubmed, doi:10.1093/neuonc/noac270.

Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite K, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS. Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol. 2023 Feb 14;25(2):424–429.